S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NYSE:ENZ

Enzo Biochem Stock Forecast, Price & News

$3.38
+0.04 (+1.20%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.34
$3.48
50-Day Range
$3.24
$4.09
52-Week Range
$1.97
$4.85
Volume
153,318 shs
Average Volume
614,798 shs
Market Capitalization
$163.84 million
P/E Ratio
19.88
Dividend Yield
N/A
Beta
0.87
30 days | 90 days | 365 days | Advanced Chart
Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.


Enzo Biochem logo

About Enzo Biochem

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
428
Year Founded
N/A

Sales & Book Value

Annual Sales
$117.73 million
Cash Flow
$0.26 per share
Book Value
$1.41 per share

Profitability

Net Income
$7.88 million
Pretax Margin
6.69%

Debt

Price-To-Earnings

Miscellaneous

Free Float
43,916,000
Market Cap
$163.84 million
Optionable
Optionable

Company Calendar

Last Earnings
10/12/2021
Today
11/28/2021
Next Earnings (Estimated)
12/08/2021
Fiscal Year End
7/31/2022

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

1138th out of 1,391 stocks

Medical Laboratories Industry

25th out of 30 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

How has Enzo Biochem's stock been impacted by Coronavirus (COVID-19)?

Enzo Biochem's stock was trading at $2.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ENZ stock has increased by 18.2% and is now trading at $3.38.
View which stocks have been most impacted by COVID-19
.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release its next quarterly earnings announcement on Wednesday, December 8th 2021.
View our earnings forecast for Enzo Biochem
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) posted its earnings results on Tuesday, October, 12th. The medical research company reported $0.07 earnings per share (EPS) for the quarter. The medical research company had revenue of $24.81 million for the quarter. Enzo Biochem had a net margin of 6.69% and a trailing twelve-month return on equity of 15.73%.
View Enzo Biochem's earnings history
.

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the following people:
  • Elazar Rabbani, Chairman, Chief Executive Officer & Secretary
  • Barry W. Weiner, President & Treasurer
  • David A. Bench, Chief Financial & Accounting Officer
  • Dieter Schapfel, Chief Medical Director & VP-Medical Affairs
  • Kara Cannon, Chief Commercialization Officer & Vice President

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (6.62%), Dimensional Fund Advisors LP (3.21%), BlackRock Inc. (3.16%), VIEX Capital Advisors LLC (3.12%), Fuller & Thaler Asset Management Inc. (1.94%) and Two Sigma Advisers LP (0.40%). Company insiders that own Enzo Biochem stock include Discovery Fund Lp Harbert and Peter J Iv Clemens.
View institutional ownership trends for Enzo Biochem
.

Which major investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., BlackRock Inc., Two Sigma Investments LP, Fuller & Thaler Asset Management Inc., and Corrado Advisors LLC.
View insider buying and selling activity for Enzo Biochem
or view top insider-selling stocks.

Which major investors are buying Enzo Biochem stock?

ENZ stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Raymond James & Associates, VIEX Capital Advisors LLC, and Neuberger Berman Group LLC.
View insider buying and selling activity for Enzo Biochem
or or view top insider-buying stocks.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $3.38.

How much money does Enzo Biochem make?

Enzo Biochem has a market capitalization of $163.84 million and generates $117.73 million in revenue each year. The medical research company earns $7.88 million in net income (profit) each year or $0.17 on an earnings per share basis.

How many employees does Enzo Biochem have?

Enzo Biochem employs 428 workers across the globe.

What is Enzo Biochem's official website?

The official website for Enzo Biochem is www.enzo.com.

Where are Enzo Biochem's headquarters?

Enzo Biochem is headquartered at 527 Madison Ave., New York NY, 10022.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at (212) 583-0100, via email at [email protected], or via fax at 212-679-7999.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.